BRD9抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: LNCAP and K562 cell lysates, Primary antibody: P09368(BRD9 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09368(BRD9 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P09368(BRD9 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

The bromodomain-containing protein 9 (BRD9) is a member of the BET (bromodomain and extraterminal) family, which plays a critical role in epigenetic regulation by recognizing acetylated lysine residues on histones. BRD9 is a core component of the non-canonical BAF (ncBAF or GBAF) chromatin remodeling complex, influencing gene expression by modulating chromatin structure. Unlike other BET proteins (e.g., BRD4), BRD9 exhibits distinct functional roles, including regulating lineage-specific genes and maintaining cellular identity. Its involvement in diseases, particularly cancer and inflammatory disorders, has garnered significant research interest. For example, BRD9 has been implicated in synovial sarcoma and acute myeloid leukemia (AML), where its dysregulation contributes to oncogenic transcriptional programs.

BRD9 antibodies are essential tools for studying its biological functions, interactions, and expression patterns. These antibodies enable techniques such as immunoprecipitation, Western blotting, and immunofluorescence, aiding in the exploration of BRD9’s role in chromatin remodeling and disease mechanisms. Additionally, BRD9-targeting probes, including selective inhibitors and degraders, are being developed for therapeutic applications. However, challenges remain in ensuring antibody specificity due to structural similarities among BET family members. Recent advancements in antibody validation, such as CRISPR-based knockout controls, have improved reliability. Research on BRD9 continues to uncover its potential as a biomarker or drug target, highlighting its importance in both basic science and translational medicine.